Innovate Corp Stock Performance
| VATE Stock | USD 10.03 0.08 0.79% |
Innovate Corp holds a performance score of 8 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.56, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Innovate Corp will likely underperform. Use Innovate Corp maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to analyze future returns on Innovate Corp.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Innovate Corp are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Innovate Corp exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.20) | Five Day Return (19.37) | Year To Date Return 98.2 | Ten Year Return (86.84) | All Time Return (75.22) |
Last Split Factor 1:10 | Dividend Date 2021-08-31 | Ex Dividend Date 2013-08-28 | Last Split Date 2024-08-09 |
1 | INNOVATE Corp. Shares Sold by Stonehill Capital Management LLC - MarketBeat | 12/05/2024 |
2 | Disposition of 9881 shares by Michael Sena of Innovate Corp at 0.7 subject to Rule 16b-3 | 12/11/2024 |
3 | Disposition of 2097902 shares by Avram Glazer of Innovate Corp subject to Rule 16b-3 | 12/16/2024 |
4 | Acquisition by Paul Voigt of 369130 shares of Innovate Corp at 0.7 subject to Rule 16b-3 | 12/27/2024 |
5 | MediBeacon Transdermal GFR System Receives FDA Approval to Assess Kidney Function | 01/17/2025 |
6 | Innovate Shares Surge 63 percent Following FDA Approval of MediBeacons Kidney Function Assessment System | 01/21/2025 |
7 | INNOVATE Corp. Sees Surge, Yet Growth Challenges Persist | 01/22/2025 |
8 | Medical technology firms kidney test gets FDA approval | 01/23/2025 |
9 | MediBeacon Transdermal GFR System receives device approval in C | 02/25/2025 |
| Begin Period Cash Flow | 82.2 M |
Innovate |
Innovate Corp Relative Risk vs. Return Landscape
If you would invest 606.00 in Innovate Corp on November 29, 2024 and sell it today you would earn a total of 397.00 from holding Innovate Corp or generate 65.51% return on investment over 90 days. Innovate Corp is currently generating 1.3691% in daily expected returns and assumes 12.1646% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Innovate, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Innovate Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innovate Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Innovate Corp, and traders can use it to determine the average amount a Innovate Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1125
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | VATE | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.16 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.37 actual daily | 27 73% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Innovate Corp is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innovate Corp by adding it to a well-diversified portfolio.
Innovate Corp Fundamentals Growth
Innovate Stock prices reflect investors' perceptions of the future prospects and financial health of Innovate Corp, and Innovate Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innovate Stock performance.
| Return On Equity | -0.19 | ||||
| Return On Asset | 0.034 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 829.71 M | ||||
| Shares Outstanding | 13.26 M | ||||
| Price To Earning | (0.07) X | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 0.11 X | ||||
| Revenue | 1.42 B | ||||
| Gross Profit | 223.5 M | ||||
| EBITDA | 69.8 M | ||||
| Net Income | (35.2 M) | ||||
| Cash And Equivalents | 24.9 M | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 771.9 M | ||||
| Current Ratio | 1.04 X | ||||
| Book Value Per Share | (12.39) X | ||||
| Cash Flow From Operations | 26.5 M | ||||
| Earnings Per Share | (3.08) X | ||||
| Market Capitalization | 131.42 M | ||||
| Total Asset | 1.04 B | ||||
| Retained Earnings | (487.3 M) | ||||
| Working Capital | 104.7 M | ||||
| Current Asset | 63 K | ||||
| Current Liabilities | 8 K | ||||
About Innovate Corp Performance
By analyzing Innovate Corp's fundamental ratios, stakeholders can gain valuable insights into Innovate Corp's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Innovate Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Innovate Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 7.79 | 12.45 | |
| Return On Tangible Assets | (0.05) | (0.05) | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | 0.23 | 0.24 |
Things to note about Innovate Corp performance evaluation
Checking the ongoing alerts about Innovate Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Innovate Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innovate Corp is way too risky over 90 days horizon | |
| Innovate Corp appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 1.42 B. Net Loss for the year was (35.2 M) with profit before overhead, payroll, taxes, and interest of 223.5 M. | |
| About 60.0% of the company outstanding shares are owned by insiders | |
| Latest headline from gurufocus.com: MediBeacon Transdermal GFR System receives device approval in C |
- Analyzing Innovate Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innovate Corp's stock is overvalued or undervalued compared to its peers.
- Examining Innovate Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innovate Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innovate Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Innovate Corp's stock. These opinions can provide insight into Innovate Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Innovate Stock analysis
When running Innovate Corp's price analysis, check to measure Innovate Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovate Corp is operating at the current time. Most of Innovate Corp's value examination focuses on studying past and present price action to predict the probability of Innovate Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovate Corp's price. Additionally, you may evaluate how the addition of Innovate Corp to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |